Key Stats for Abbott Laboratories Stock
- Price change for Abbott Laboratories stock: -6%
- $ABT Share Price as of Apr. 16: $95
- 52-Week High: $139
- $ABT Stock Price Target: $131
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Abbott Laboratories (ABT) stock dropped 6% after the company reported Q1 2026 earnings on April 16.
- The results were mixed.
- Revenue grew 8% year-over-year to $11.2 billion, beating estimates by $160 million. But that wasn’t enough to offset disappointing guidance.
- For Q2, Abbott sees adjusted EPS of $1.25 to $1.31. Analysts were expecting $1.36. That’s a meaningful miss, and the market reacted quickly.
- Full-year guidance was also cut. Abbott now forecasts 2026 adjusted EPS of $5.38 to $5.58, down from its prior range of $5.55 to $5.80.
- The main reason is the $21 billion acquisition of Exact Sciences, which closed in late March and added $0.20 of earnings dilution this year.
CEO Robert Ford addressed the guidance cut directly, framing it as a deliberate choice rather than a sign of underlying weakness.
He noted that rolling Exact Sciences into comparable reporting gives investors a cleaner view of the new Abbott portfolio going forward.
On the positive side,
- the MedTech division delivered 13% growth in Q1, led by strong performances in electrophysiology, heart failure, and rhythm management.
- The Cologuard cancer screening business, now part of Abbott through Exact Sciences, grew mid-teens on a comparable basis.
The weak spot was the Nutrition segment.
Abbott cut prices in Q4 2025 to reignite volume growth, and early signs suggest it’s working, but the recovery is still in early stages.
A softer-than-expected respiratory testing season also weighed on Diagnostics in the quarter.
See analysts’ growth forecasts and price targets for Abbott Laboratories stock (It’s free) >>>
What the Market Is Telling Us About Abbott Laboratories Stock
Abbott Laboratories stock was already carrying high expectations heading into earnings. A guidance miss — even one explained by acquisition dilution — was enough to trigger a sharp sell-off.
The business itself has real strengths.
- MedTech is growing fast,
- Cologuard is a compelling long-term asset, and
- management sounded confident about a stronger second half.
But Abbott Laboratories stock is now under pressure until investors see evidence that the Exact Sciences integration delivers and that Nutrition continues to recover.
Abbott Laboratories stock could look more attractive once the acquisition noise settles and growth reaccelerates in the back half of the year.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Abbott Laboratories Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
